Leju Finance Li LiOn December 14, the Shenzhen Stock Exchange announced that it would terminate the review of the initial public offering of Guochuang Pharmaceutical** and its listing on the GEM.
It is reported that on December 27, 2022, the Shenzhen Stock Exchange accepted the application documents for the initial public offering of Shanghai Guochuang Pharmaceutical Co., Ltd. and its listing on the GEM, and reviewed it in accordance with laws and regulations.
On December 12, 2023, Guochuang Pharmaceutical submitted the "Application for the Withdrawal of the Application Documents for the Initial Public Offering** and Listing on the Growth Enterprise Market" to the Shenzhen Stock Exchange, and the sponsor submitted the "Application for Minsheng ** Shares*** on the Withdrawal of the Application Documents for the Initial Public Offering** and Listing on the Growth Enterprise Market of Shanghai Guochuang Pharmaceutical Shares" to the Shenzhen Stock Exchange.
In accordance with the relevant regulations, the Shenzhen Stock Exchange decided to terminate the review of Guochuang Pharmaceutical's initial public offering** and listing on the GEM.
The company is a comprehensive pharmaceutical enterprise integrating R&D, production, sales and other businesses, and is committed to providing patients with safe and effective pharmaceutical products with large clinical needs. From 2020 to 2022, the company's operating income was 41,884890,000 yuan, 38,954320,000 yuan, 44,654120,000 yuan, net profit attributable to owners of the parent company after deducting non-recurring gains and losses were 3,832640,000 yuan, 6,110$500,000 and $7,638710,000 yuan, with a compound annual growth rate of 4118%, with strong growth.
Guochuang Pharmaceutical's existing core products are all acquired first.
From 2020 to 2022 (reporting period), the proportion of revenue from Guochuang Pharmaceutical's self-produced products was ., respectively51%, and the main business income realized by self-produced products was 21.2 billion yuan, 19.9 billion and 25.2 billion yuan, the main products are pregabalin capsules, telmisartan tablets, Yixinshu granules and Neckkang capsules. **The proportion of product revenue is .37% and 3307%, and the rest is income from extension services.
Specifically, the production approval and core technology of Guochuang Pharmaceutical's core product, pregabalin capsules, were acquired from Chongqing Saiwei in 2018, and the proportion of this product in Guochuang Pharmaceutical's revenue during the reporting period was as high as46% and 3705%, accounting for the company's gross profit respectively11% and 6202%。The production approval and core technology of other core products, Yixinshu Granules and Neckkang Capsules, were acquired by Shandong Zhongtai in 2021.
During the reporting period, the marketing expenses of the company's sales expenses were 12,148090,000 yuan, 6,409$510,000, $6,078700,000 yuan, accounting for the proportion of sales expenses respectively29%。In 2021 and 2022, the company's marketing expenses decreased significantly, mainly due to the fact that its main product, pregabalin capsule 75mg*20 capsules, won the bid for the fourth batch of national centralized procurement, and the company did not need to carry out a large number of marketing activities for this specification product.
At the end of the reporting period, the company's net accounts receivable were 14,633190,000 yuan, 15,081640,000 yuan, 13,916090,000 yuan, accounting for the proportion of current assets were .33%, which is an important part of the company's current assets.
At the end of the reporting period, the carrying value of the company's inventory was 4,232220,000 yuan, 4,275500,000 yuan, 4,496360,000 yuan, accounting for the proportion of current assets00%。
Related companies: Guochuang Pharmaceutical.